Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Pneumonia 1Lymphoma, Follicular 1Cytokine Release Syndrome 1COVID-19 1

Interventions

Standard of Care 3COH04S1 COVID-19 vaccine 2remdesivir 1palbociclib 1ogalvibart 1crexavibart 1cilgavimab and tixagevimab drug combination 1acalabrutinib 1XAV-19 1Therapeutics 1Surveys and Questionnaires 1Specimen Handling 1Rabeprazole 1Prednisone 1Methylprednisolone 1IBIO123 1Glucocorticoids 1Gelsolin 1Dexamethasone 1CVnCoV COVID-19 vaccine 1COVID-19 Vaccines 1COVID-19 Serotherapy 1Atorvastatin 13-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid 11-palmityl-2-(4-carboxybutyl)-sn-glycero-3-phosphocholine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
COVID-19 × Gelsolin × Lymphoid × Clear all
NCT04358406 2023-11-28

Rhu-pGSN for Severe Covid-19 Pneumonia

BioAegis Therapeutics Inc.

Phase 2 Completed
64 enrolled 17 charts
Lymphoid

Cytokine Release Syndrome, COVID-19, Lymphoma, Follicular, Pneumonia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡